Loss of ATF3 promotes hormone-induced prostate carcinogenesis and the emergence of CK5 + CK8 + epithelial cells

Z. Wang, Jaejik Kim, Yong Teng, Hanfei Ding, J. Zhang, T. Hai, John Kenneth Cowell, Chunhong Yan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Steroid sex hormones can induce prostate carcinogenesis, and are thought to contribute to the development of prostate cancer during aging. However, the mechanism for hormone-induced prostate carcinogenesis remains elusive. Here, we report that activating transcription factor 3 (ATF3) - a broad stress sensor - suppressed hormone-induced prostate carcinogenesis in mice. Although implantation of testosterone and estradiol (T+E 2) pellets for 2 months in wild-type mice rarely induced prostatic intraepithelial neoplasia (PIN) in dorsal prostates (one out of eight mice), the loss of ATF3 led to the appearance of not only PIN but also invasive lesions in almost all examined animals. The enhanced carcinogenic effects of hormones on ATF3-deficient prostates did not appear to be caused by a change in estrogen signaling, but were more likely a consequence of elevated androgen signaling that stimulated differentiation of prostatic basal cells into transformation-preferable luminal cells. Indeed, we found that hormone-induced lesions in ATF3-knockout mice often contained cells with both basal and luminal characteristics, such as p63 + cells (a basal-cell marker) showing luminal-like morphology, or cells double-stained with basal (CK5 +) and luminal (CK8 +) markers. Consistent with these findings, low ATF3 expression was found to be a poor prognostic marker for prostate cancer in a cohort of 245 patients. Our results thus support that ATF3 is a tumor suppressor in prostate cancer.

Original languageEnglish (US)
Pages (from-to)3555-3564
Number of pages10
JournalOncogene
Volume35
Issue number27
DOIs
StatePublished - Jul 7 2016

Fingerprint

Activating Transcription Factor 3
Prostate
Carcinogenesis
Epithelial Cells
Hormones
Prostatic Intraepithelial Neoplasia
Prostatic Neoplasms
Gonadal Steroid Hormones
Knockout Mice
Androgens
Testosterone
Estradiol
Estrogens

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Loss of ATF3 promotes hormone-induced prostate carcinogenesis and the emergence of CK5 + CK8 + epithelial cells. / Wang, Z.; Kim, Jaejik; Teng, Yong; Ding, Hanfei; Zhang, J.; Hai, T.; Cowell, John Kenneth; Yan, Chunhong.

In: Oncogene, Vol. 35, No. 27, 07.07.2016, p. 3555-3564.

Research output: Contribution to journalArticle

@article{99ffdb4913db41a2a21f8c692094c649,
title = "Loss of ATF3 promotes hormone-induced prostate carcinogenesis and the emergence of CK5 + CK8 + epithelial cells",
abstract = "Steroid sex hormones can induce prostate carcinogenesis, and are thought to contribute to the development of prostate cancer during aging. However, the mechanism for hormone-induced prostate carcinogenesis remains elusive. Here, we report that activating transcription factor 3 (ATF3) - a broad stress sensor - suppressed hormone-induced prostate carcinogenesis in mice. Although implantation of testosterone and estradiol (T+E 2) pellets for 2 months in wild-type mice rarely induced prostatic intraepithelial neoplasia (PIN) in dorsal prostates (one out of eight mice), the loss of ATF3 led to the appearance of not only PIN but also invasive lesions in almost all examined animals. The enhanced carcinogenic effects of hormones on ATF3-deficient prostates did not appear to be caused by a change in estrogen signaling, but were more likely a consequence of elevated androgen signaling that stimulated differentiation of prostatic basal cells into transformation-preferable luminal cells. Indeed, we found that hormone-induced lesions in ATF3-knockout mice often contained cells with both basal and luminal characteristics, such as p63 + cells (a basal-cell marker) showing luminal-like morphology, or cells double-stained with basal (CK5 +) and luminal (CK8 +) markers. Consistent with these findings, low ATF3 expression was found to be a poor prognostic marker for prostate cancer in a cohort of 245 patients. Our results thus support that ATF3 is a tumor suppressor in prostate cancer.",
author = "Z. Wang and Jaejik Kim and Yong Teng and Hanfei Ding and J. Zhang and T. Hai and Cowell, {John Kenneth} and Chunhong Yan",
year = "2016",
month = "7",
day = "7",
doi = "10.1038/onc.2015.417",
language = "English (US)",
volume = "35",
pages = "3555--3564",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "27",

}

TY - JOUR

T1 - Loss of ATF3 promotes hormone-induced prostate carcinogenesis and the emergence of CK5 + CK8 + epithelial cells

AU - Wang, Z.

AU - Kim, Jaejik

AU - Teng, Yong

AU - Ding, Hanfei

AU - Zhang, J.

AU - Hai, T.

AU - Cowell, John Kenneth

AU - Yan, Chunhong

PY - 2016/7/7

Y1 - 2016/7/7

N2 - Steroid sex hormones can induce prostate carcinogenesis, and are thought to contribute to the development of prostate cancer during aging. However, the mechanism for hormone-induced prostate carcinogenesis remains elusive. Here, we report that activating transcription factor 3 (ATF3) - a broad stress sensor - suppressed hormone-induced prostate carcinogenesis in mice. Although implantation of testosterone and estradiol (T+E 2) pellets for 2 months in wild-type mice rarely induced prostatic intraepithelial neoplasia (PIN) in dorsal prostates (one out of eight mice), the loss of ATF3 led to the appearance of not only PIN but also invasive lesions in almost all examined animals. The enhanced carcinogenic effects of hormones on ATF3-deficient prostates did not appear to be caused by a change in estrogen signaling, but were more likely a consequence of elevated androgen signaling that stimulated differentiation of prostatic basal cells into transformation-preferable luminal cells. Indeed, we found that hormone-induced lesions in ATF3-knockout mice often contained cells with both basal and luminal characteristics, such as p63 + cells (a basal-cell marker) showing luminal-like morphology, or cells double-stained with basal (CK5 +) and luminal (CK8 +) markers. Consistent with these findings, low ATF3 expression was found to be a poor prognostic marker for prostate cancer in a cohort of 245 patients. Our results thus support that ATF3 is a tumor suppressor in prostate cancer.

AB - Steroid sex hormones can induce prostate carcinogenesis, and are thought to contribute to the development of prostate cancer during aging. However, the mechanism for hormone-induced prostate carcinogenesis remains elusive. Here, we report that activating transcription factor 3 (ATF3) - a broad stress sensor - suppressed hormone-induced prostate carcinogenesis in mice. Although implantation of testosterone and estradiol (T+E 2) pellets for 2 months in wild-type mice rarely induced prostatic intraepithelial neoplasia (PIN) in dorsal prostates (one out of eight mice), the loss of ATF3 led to the appearance of not only PIN but also invasive lesions in almost all examined animals. The enhanced carcinogenic effects of hormones on ATF3-deficient prostates did not appear to be caused by a change in estrogen signaling, but were more likely a consequence of elevated androgen signaling that stimulated differentiation of prostatic basal cells into transformation-preferable luminal cells. Indeed, we found that hormone-induced lesions in ATF3-knockout mice often contained cells with both basal and luminal characteristics, such as p63 + cells (a basal-cell marker) showing luminal-like morphology, or cells double-stained with basal (CK5 +) and luminal (CK8 +) markers. Consistent with these findings, low ATF3 expression was found to be a poor prognostic marker for prostate cancer in a cohort of 245 patients. Our results thus support that ATF3 is a tumor suppressor in prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=84977645422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977645422&partnerID=8YFLogxK

U2 - 10.1038/onc.2015.417

DO - 10.1038/onc.2015.417

M3 - Article

VL - 35

SP - 3555

EP - 3564

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 27

ER -